Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W8RX
|
|||
| Former ID |
DIB012616
|
|||
| Drug Name |
Sitimagene ceradenovec
|
|||
| Synonyms |
Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark
Click to Show/Hide
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Discontinued in Phase 3 | [1] | |
| Company |
Ark Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymidine kinase 1 (TK1) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015264) | |||
| REF 2 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.